Welcome to our dedicated page for Adastra Holdings news (Ticker: XTXXF), a resource for investors and traders seeking the latest updates and insights on Adastra Holdings stock.
News and disclosures about Adastra Holdings Ltd. (XTXXF) focus on its role as a cannabis processor and manufacturer of ethnobotanical and cannabis products for lawful adult-use and medical markets. Adastra’s updates frequently highlight its Health Canada licensed operations, its concentrates brands Phyto Extractions and Endgame Extracts, and its distribution reach through Canadian retailers.
Investors and observers following Adastra’s news can expect coverage of strategic transactions, corporate governance changes and capital structure developments. Recent releases describe the sale of subsidiaries such as Adastra Labs Holdings (2019) Ltd., 1178562 B.C. Ltd., Adastra Brands Inc., and 1225140 B.C. Ltd. (dba Perceive MD), which the company states are intended to strengthen its balance sheet, reduce debt and streamline operations while maintaining access to its existing facility and brand trademarks through lease and licensing agreements.
Adastra’s news flow also includes information on board and management changes, such as director appointments and resignations, as well as updates on interim and permanent leadership roles. The company has issued clarifications on its management structure and described consulting arrangements for financial reporting and budgeting support.
Capital markets updates, including the announcement of a proposed 10:1 share consolidation on the Canadian Securities Exchange, are another recurring theme in Adastra’s communications. In addition, the company provides details on shareholder meetings, voting procedures and access to proxy materials through Canadian securities platforms. Readers who follow Adastra’s news page can track how the company manages its cannabis processing operations, brand portfolio and corporate structure within a regulated industry environment.
Adastra Holdings Ltd. (symbol: XTXXF) appointed Calum Maschi as a director effective April 30, 2026, replacing Jonathan Edwards who resigned.
Mr. Maschi is described as a construction professional with over fifteen years of experience on large industrial, institutional and infrastructure projects, including management roles on LNG Canada. The company thanked Mr. Edwards for his contributions.
Adastra Holdings (OTC:XTXXF) announced that Paul Morgan has resigned as a director effective April 28, 2026. The company thanked Mr. Morgan for his service and said the remaining director is identifying candidates to fill board vacancies and will provide an update when available.
Adastra Holdings (OTC:XTXXF) announced on March 2, 2026 that wholly owned Adastra Labs agreed to sell certain cryoethanol and hydrocarbon extraction and packaging equipment for $166,225 and simultaneously lease the assets back for an annual fee of $25,000 plus GST.
The company said the sale-and-leaseback is intended to strengthen the balance sheet and reduce debt while avoiding material disruption to operations. The Transactions are expected to close shortly and remain subject to customary conditions. The company also disclosed that director Mark Qvist resigned effective February 28, 2026.
Adastra Holdings (OTC:XTXXF) announced on October 15, 2025 that it completed the sale of all issued and outstanding shares of three wholly owned subsidiaries for aggregate consideration of $4,000,000. The consideration comprised $495,000 for Adastra Labs via a 12% interest-bearing promissory note, $3,500,000 satisfied by the purchaser's assumption of existing mortgage debt on the Langley, BC property, and $5,000 cash for Adastra Brands.
As part of closing, the seller arranged a leaseback: 1178562 will lease 13,000 sq ft to Adastra Labs Inc. for $35,000/month, and Adastra Brands licensed trademarks to the company for an annual license fee. The company said these transactions strengthen the balance sheet, reduce debt, and allow continued operations at the existing facility while retaining brand use.
Adastra Holdings (OTC: XTXXF) announced agreements dated October 8, 2025 to sell three wholly owned subsidiaries for an aggregate consideration of $4,000,000. The consideration includes a $495,000 12% interest-bearing promissory note for Adastra Labs, $3,500,000 satisfied by purchaser assumption of the existing mortgage on 1178562's Langley, BC property, and $5,000 cash for Adastra Brands.
Related agreements include a leaseback: 1178562 will lease 13,000 sq ft to Adastra Labs Inc. for $35,000 per month, and an intellectual property license from Adastra Brands to the company for nominal consideration. The company said the transactions aim to strengthen the balance sheet, reduce debt, and streamline operations; closing remains subject to customary conditions.
Adastra Holdings (CSE: XTRX) has appointed Mark Qvist to its board of directors, effective February 28, 2025. Qvist brings over 25 years of experience in geotechnical, environmental, and botanical sectors. He currently serves as CEO of Life Cycle Botanics, a premier nursery he founded in 2019 that supplies plant genetics to licensed producers across Canada.
Prior to this, Qvist co-owned On Track Drilling, where he enhanced specialized drilling operations, strengthened regulatory compliance, and drove strategic business development. He replaces Andrew Hale, who resigned as director on February 14, 2025.
Adastra Holdings (CSE: XTRX) (FSE: D2EP), a leading cannabis processor and producer of concentrates brands, announced that Andrew Hale has resigned from his position as director, effective February 14, 2025. The company's board of directors is actively searching for a replacement to fill the upcoming vacancy and will provide updates when available. Adastra, which focuses on product innovation and commercialization for adult-use and medical markets, is known for producing two of Canada's top concentrate brands.
Adastra Holdings (CSE: XTRX) (FSE: D2E0), a cannabis processor and producer of concentrates, has issued a clarification regarding its current management structure following a review by the British Columbia Securities Commission. Lachlan McLeod resigned as Interim CEO on September 26, 2024, and as CFO and Corporate Secretary on October 5, 2024.
McLeod continues to provide financial services through Stornoway Consulting Corp, under an agreement effective until May 31, 2025. The scope includes assistance with financial statements preparation, annual budget planning, and support for external auditors. Currently, management activities are being handled by the board of directors: Jon Edwards, Andrew Hale, and Paul Morgan. The company is actively seeking candidates to fill the CEO, CFO, and Corporate Secretary positions.
Adastra Holdings (CSE: XTRX) (FSE: D2E0) has announced its 2024 Annual General Meeting (AGM) will be held virtually on December 13, 2024, at 1:00 PM Pacific Time. The meeting agenda includes reviewing audited financial statements for 2022-2023, electing directors, reappointing MNP LLP as auditors, and other business matters.
Shareholders can participate through virtual attendance, with registered shareholders and appointed proxyholders needing to pre-register by December 11, 2024, to vote and speak during the meeting. All proxy-related materials are available on SEDAR+ and the company's website. The company encourages shareholders to submit proxy forms or voting instructions in advance through National Securities Administrators
Adastra Holdings (CSE: XTRX) has announced the sale of Perceive MD through a Share Purchase Agreement between its subsidiary Adastra Labs and Majik Psilocybin Ventures, effective November 5, 2024. The transaction involves the sale of all issued and outstanding shares (100 class A and 100 class B common shares) of Perceive MD. The purchase price was nominal, with the purchaser assuming all of Perceive MD's obligations. This strategic move aligns with Adastra's focus on its core business areas and emerging market opportunities.